Pipeline

Developing Oral Biologics to Treat Disease at its Origin

~ 75 percent of the entire immune system is located in the GI tract.
With privileged access to the immune-cell rich GI environment, AMT’s lead product candidates are designed to intercept disease biology at critical sites by directly targeting signaling axes within the GI tract.

AMT has a robust pipeline of oral biologic product opportunities engineered to gain privileged access to the immune system and the hepatic portal system by crossing intestinal epithelial barriers. This privileged access provides the opportunity to address disease at its point of origin and creates the potential to achieve greater efficacy and tolerability than seen with parenterally administered therapeutics, particularly in the areas of immunology and inflammation, liver and metabolic diseases.

Program Therapeutic Area Preclinical Phase 1 Phase 2
AMT-101 Oral GI-selective immunomodulator (IL-10 fusion) Immunology & Inflammation
Phase 1a/b
AMT-126Oral GI-selective barrier function defect correction (IL-22 fusion) Immunology & Inflammation, Liver, Metabolic Diseases
 
AMT-115Oral GI-selective TNFα inhibitor fusion Immunology & Inflammation
 
AMT-221Oral incretin peptide Diabetes & Obesity, Liver
 
AMT-205Oral endocrine protein Metabolic Diseases
 
Candidate/ProgramTherapeutic AreaPhase
AMT-101
Oral GI-selective immunomodulator (IL-10 fusion)
Immunology & Inflammation Phase 1/2
AMT-126
Oral GI-selective barrier function defect correction (IL-22 fusion)
Immunology & Inflammation, Liver, Metabolic Diseases Preclinical
AMT-115
Oral GI-selective TNFa inhibitor fusion
Immunology & Inflammation Preclinical
AMT-221
Oral incretin peptide
Diabetes & Obesity, Liver Preclinical
AMT-205
Oral endocrine protein
Metabolic Diseases Preclinical